Lobbying Activity Report

2606-42904

Organization: sanofi-aventis Canada Inc.
Did any other entity with a direct interest in the outcome of this lobbying activity work together for the purpose of performing this lobbying activity? Yes
Lobbying activity performed with and/or on behalf of the following other entities with a direct interest in the outcome of the lobbying activity that worked together for the purpose of performing this lobbying activity: Innovative Medicines Canada
Associated registration: 8767-2606-20
Lobbying Activity date: 2025-05-16
Arranged a meeting: No
Posted date: 2025-06-05

In-house lobbyists who participated in the lobbying activity: Daniel Kennedy
Senior Public Office Holders who were lobbied in this activity: Ian Rongve, ADM
Health
 
Subject Matter of the Lobbying Activity
Specific Topics of Lobbying Communications Intended Outcomes Associated Subject Matters
To actively promote the contributions and positive impact of pharmaceutical innovation and the innovative pharmaceutical industry in British Columbia and to increase awareness of the value of innovative therapies on the healthcare system. Ensure any changes to pharmaceutical legislation support appropriate government reimbursement of innovative pharmaceuticals.
  • Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
 Health
 
Senior officer who filed this Lobbying Activity Report: James Guy
 
The above name is that of the most senior paid officer who is responsible for filing a Lobbying Activity Report for the organization (the Designated Filer), whether that person participated in this lobbying activity or not.
Date Modified: